Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.38 |
| ▸ | LPL | P06858 | 12/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | SNCA | P37840 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA3 | P07451 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16277767 | 0.80 | DGAT1 (0.39) | CA1CA2CA9NPC1DGAT1 | |
| SCHEMBL30051335 | 0.80 | LPL (0.40) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL16660866 | 0.78 | LIPG (0.40) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL27153282 | 0.77 | NPC1 (0.39) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL22967310 | 0.77 | DGAT1 (0.43) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL16283835 | 0.77 | PRMT5 (0.32) | CA1CA2CA9NPC1DGAT1 | |
| SCHEMBL16278455 | 0.76 | DGAT1 (0.37) | LIPGLPLNPC1DGAT1 | |
| SCHEMBL1440980 | 0.75 | LPL (0.40) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL10276614 | 0.75 | LPL (0.40) | LIPGLPLCA1CA2CA9 | |
| SCHEMBL16661160 | 0.75 | LPL (0.39) | LIPGLPLCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| US-9249163-B2 | PDE10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV. (BE) | 2016-02-02 | — | — | US | disclosed |
| US-9193736-B2 | PDE 10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-9193736-B2 | PDE 10a inhibitors for the treatment of type II diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2015-11-24 | — | — | US | disclosed |
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | JANSSEN PHARMACEUTICA, NV (BE) | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364413-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | LIPG 77/4885LPL 68/4885CA1 3580/4885 |
| US-20140364414-A1 | PDE 10a Inhibitors for the Treatment of Type II Diabetes | PDE2A, PDE3B, PDE3A | LIPG 77/4885LPL 68/4885CA1 3580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.